N itric oxide (NO) has been implicated in a wide range of physiological functions including endotheliumdependent relaxation of blood vessels, inhibition of platelet aggregation, and vascular smooth muscle cell proliferation. 1 In target cells such as vascular smooth muscle cells and platelets, NO activates the key enzyme that mediates vascular relaxation, the soluble guanylyl cyclase (sGC) to convert GTP to cGMP. 2 The increase in cGMP content in vascular smooth muscle cells is associated with an activation of cGMP-dependent protein kinase type I␣ (cGKI␣) and subsequent phosphorylation of numerous intracellular proteins. 3 The sGC was purified as a heterodimeric heme-containing protein, consisting of a larger ␣ 1 (82 kDa) and a smaller ␤ 1 (Ϸ70 kDa) subunit. 4, 5 The cDNA clones for both ␣ 1 and ␤ 1 subunits were isolated from different species including rat. 6, 7 Moreover, sGC is the major physiological target of NO-donor compounds such as molsidomine. 8 Recently, an NOindependent direct activator of sGC has been introduced, YC-1. 9 Endothelial dysfunction, characterized by an impairment of endothelium-dependent relaxation, is associated with hypertension and hypercholesterolemia 10, 11 and is thought to be an early common mechanism in the development of atherosclerosis. A decreased bioavailability of endothelium-derived NO has been suggested to be responsible for endothelial dysfunction and, hence, hypertension. 12, 13 Furthermore, systemic administration of NOS inhibitors markedly increases arterial blood pressure, 14 and knocking out the gene encoding endothelial NO synthase (eNOS) in mice results in the development of hypertension and abolishes the endotheliumdependent relaxation elicited by acetylcholine. 15 However, an increase in the endothelial superoxide anion (O 2 Ϫ ) production has also been implicated in the development of endothelial dysfunction in hypertension. Indeed, an enhanced formation of O 2 Ϫ has been demonstrated in vessels from spontaneously hypertensive rats (SHR). 16 An increase in the production of O 2 Ϫ rapidly scavenges NO to form the cytotoxic metabolite of NO and O 2 Ϫ , peroxynitrite and hence reduces the bioavailability of NO. 17 This may explain the findings that in SHR the effectiveness of NO is reduced, whereas the NO release remains unaffected or even is increased. 18 -20 It is unclear, however, whether alterations in the sGC/cGMP/cGKI␣ pathway are involved also in the pathogenesis of hypertension. 21 ,22 Therefore, we tested the hypothesis that alterations in the sGC pathway may also contribute to the development of hypertension.
In the present study, we investigated the endotheliumindependent relaxation of aortic rings mediated by sGC as well as the expression (protein and mRNA) of the ␣ 1 and ␤ 1 subunit of sGC in aortic rings, hearts, kidneys, and brains from young (6 weeks old) and aging (17 months old) SHR and normotensive Wistar-Kyoto rats (WKY). In addition, we determined the mRNA expression of cGMP-dependent protein kinase type I␣ (cGKI␣) in aortic rings and hearts from these animals.
Materials and Methods

Animals
The studies were performed using aortas, hearts, brains, and kidneys from young (6 weeks old) and aging (17 months old) male SHR and WKY. Before the experiments, rats were housed under standardized conditions of temperature, humidity, and light. The animals had free access to standard diet (Altromin maintenance diet 1320; sodium content 0.2%) and drinking water ad libitum. All experiments were performed in accordance with the German animal protection law.
Vascular Reactivity Studies
SHR and WKY were decapitated, and the descending aorta was removed, cleaned of connective tissue, and dissected into 3 sections. The upper section (20 mm) was immediately frozen in liquid nitrogen for reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot analyses. The lower section (10 mm) was used for the measurement of cGMP formation, whereas the remaining part of the aorta was cut into 4 rings (3 mm in length) and the endothelium was mechanically removed. The rings were equilibrated in an organ bath (Schuler-Organbad; Hugo Sachs Elektronik) for 30 minutes under a resting tension of 1 g in carbonated (95% O 2 /5% CO 2 ) Krebs-Henseleit solution, pH 7.4 (composition in mmol/L: Na 11.1) , in the presence of the cyclooxygenase inhibitor indomethacin (1 mol/L). Subsequently, rings were contracted with phenylephrine (PE, 1 mol/L), and the functional loss of the endothelium was tested by recording the relaxation to acetylcholine (1 mol/L). After a 30-minute washout period, rings were contracted with 1 mol/L PE, and the relaxant response to a cumulative dose of YC-1 or sodium nitroprusside (SNP) was assessed in the presence or absence of superoxide dismutase (SOD, 0.1 mol/L) and/or the phosphodiesterase (PDE) V inhibitor zaprinast (30 mol/L). At the end of the experiments, the selective inhibitor of sGC, ODQ, 23 was added.
Determination of cGMP Content in Isolated Blood Vessels
After mechanical removal of the endothelium, the lower part of the aorta was cut into 4 rings (3 mm in length) and treated with the PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX; 100 mol/L) for 15 minutes in microtubes. After this period, aortic rings were incubated with vehicle (0.3% DMSO), YC-1 (30 mol/L), ODQ (10 mol/L), or the combination of YC-1 (30 mol/L) and ODQ (10 mol/L) for 15 minutes. At the end of the incubation, aortic rings were immediately frozen in liquid nitrogen and stored at Ϫ80°C. cGMP was extracted by the addition of 4 volumes of HClO 4 (1 N) followed by sonification for 15 seconds and centrifugation (15 minutes, 13 000g). The pellets were used for protein determination according to the method of Bradford. 24 The supernatant (100 L) was neutralized with 100 L KOH (1 N), sonicated, and centrifuged again (2 minutes, 3000g) and then used for the determination of cGMP by EIA (Amersham Life Science).
Determination of sGC Protein Expression
Frozen rat aorta, heart, kidney, and brain tissue powder were homogenized in 200 L sample buffer (Novex) supplemented with PMSF (1 mmol/L), pepstatin A (1 mol/L), leupeptin (2 mol/L), and MESNA (0.2 mol/L) and subsequently centrifuged at 13 000g for 30 minutes at 4°C. The supernatant was boiled for 10 minutes and then loaded (50 g protein/20 L) onto 4% to 12% Bis-Tris polyacrylamide gels (Novex). The gels were run at 200 V for 50 minutes in a MOPS-SDS running buffer, and subsequently separated proteins were transferred to nitrocellulose (Novex) by semidry Western blotting. Blots were blocked overnight at 4°C in TBST (20 mmol/L Tris-HCl, 137 mmol/L NaCl [pH 7.6], and 0.05% Tween-20) containing 5% nonfat dry milk and washed 3 times in TBST, and the blots were incubated with polyclonal peptide-specific antibodies to either the ␣ 1 or the ␤ 1 subunit of sGC as described. 25 Subsequently, blots were incubated with an HRP-conjugated secondary antibody (Dianova, 1:10 000) in TBST for 1 hour, developed by using an enhanced HRP/luminol chemiluminescence reaction (ECL Western blotting detection reagents, NEN Life Science Products), and exposed to X-ray film for 30 to 60 seconds. The autoradiographs were analyzed by scanning densitometry.
Determination of RNA Expression by PCR Analysis
Total RNA was prepared from the indicated tissues according to the manufacturer's protocol using TRIzol reagent (Gibco BRL Life Technologies, Inc). RT-PCR was performed using the GeneAmp RNA PCR kit (Perkin-Elmer). cDNA was generated by incubating 2 g of the total RNA in the presence of Oligo d(T)16 primer in a 20-L reaction for 10 minutes at room temperature. Subsequently, the reaction mixture was incubated at 42°C for 30 minutes and at 99°C for 5 minutes. The reverse transcription was stopped by incubating at 0°C for 5 minutes. After an initial denaturation step at 94°C, 20 to 35 PCR cycles were performed as follows: 1 minute at 94°C, 3 minutes at 55°C, and 1 minute at 72°C. In each PCR, the cDNAs for the sGC subunits ␤ 1 (70 kDa) and ␣ 1 (82 kDa), cGMP-dependent protein kinase, and GAPDH were coamplified. The optimal cycle number for each primer was determined by a PCR run for cycle dependency under the described conditions. The primers used to amplify sGC ␣ 1 and ␤ 1 , 26 cGKI␣, 27 and GAPDH are provided in Table 1 .
The PCR amplifications were performed in a reaction mixture containing 2 mmol/L MgCl 2 and 20% Q-solution (Quiagen GmbH). The amplified cDNAs were size-fractionated using a 6% Tris-boric acid-EDTA gel (Novex) and stained with ethidium bromide. The fluorescence was detected densitometrically using a FluorImager (Molecular Dynamics GmbH).
Statistical Analysis
Results are expressed as meanϮSEM. Unless otherwise stated, each of the studies was performed in a minimum of 5 rats. Comparisons 
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were performed by ANOVA or paired and unpaired Student's t tests when appropriate. The Bonferroni correction for multiple comparison was used to determine the levels of significance of the P values.
Results
General Data
Global parameters of young and aging WKY and SHR are shown in Table 2 . The systolic blood pressure of aging SHR as measured by tail-cuff plethysmography was significantly higher when compared with young and aging WKY as well as to young SHR. In addition, body weight of aging WKY was significantly higher when compared with age-matched SHR. However, the basal heart rate was not significantly different between groups.
Endothelium-Independent Vasodilator Responses in Aortic Rings and cGMP Content
In aortic rings preconstricted with PE, the endotheliumindependent, direct activator of sGC YC-1 induced a Figure 1B ). The addition of SOD (0.1 mol/L) to PE-constricted aortic rings resulted in a small but stable relaxation that was comparable in aortic rings from aging WKY (21Ϯ5%) and SHR (23Ϯ4%). Interestingly, the addition of SOD shifted the concentration-response curve to YC-1 in aortic rings from aging SHR significantly to the left and, hence, partially (46Ϯ6%) restored the impaired relaxation to YC-1 when compared with age-matched WKY ( Figure 1B) . In contrast, SOD had only a small but insignificant effect on the relaxant response to YC-1 in aortic rings from aging WKY ( Figure  1B ). In addition, cumulative concentrations of the selective cGMP PDE V inhibitor zaprinast caused only relatively small relaxations of aortic rings from young and aging SHR and WKY, which were not significantly different between both strains ( Figure 1C and 1D) . In PE-constricted aortic rings from young and aging WKY and SHR, pretreatment of aortic rings with a single concentration of zaprinast (30 mol/L, which, unlike cumulative concentrations, does not affect isometric force relative to vehicle) significantly potentiated the vasorelaxant response to YC-1. The EC 50 for YC-1 in the presence of zaprinast was not significantly different between young WKY and SHR (WKY 0.9Ϯ1.1 mol/L, SHR 0.6Ϯ1.2 mol/L) ( Figure 1C ). In contrast, the concentrationresponse curve to YC-1 in the presence of zaprinast (30 mol/L) in aortic rings from aging SHR was significantly shifted to the right when compared with age-matched WKY as well as to young WKY and SHR (EC 50 : aging SHR 7.1Ϯ1.3 mol/L, aging WKY 1.4Ϯ1.7; PϽ0.05) ( Figure 1D) .
Finally, the addition of SOD also shifted the concentrationresponse curves to YC-1 or SNP in the presence of zaprinast in aortic rings from aging SHR significantly to the left and, hence, partially (39Ϯ9%) restored the impaired relaxation to YC-1 when compared with age-matched WKY (data not shown). In all groups, the relaxant response of YC-1 in endothelium-denuded aortic rings was reversed by the sGC inhibitor ODQ (10 mol/L), and similar results were obtained when the NO donor compound SNP was used instead of YC-1 (data not shown).
The basal content of cGMP in aortic rings from both young (y) and aging (o) SHR was significantly lower when compared with WKY (yWKY 2.3Ϯ0.4 pmol/mg protein, oWKY 1.9Ϯ0.5 pmol/mg protein, ySHR 0.2Ϯ0.1 pmol/mg protein, oSHR 0.2Ϯ0.1 pmol/mg protein; PϽ0.05) (Figure 2A ). However, stimulation with YC-1 (30 mol/L) resulted in similar cGMP levels in aortic rings from young WKY (40Ϯ6 pmol/mg protein) and young SHR (37Ϯ10 pmol/mg protein) ( Figure 2B ). In contrast, in aortic rings from aging SHR, the increase in the levels of cGMP caused by YC-1 was significantly reduced when compared with age-matched WKY (oSHR 60Ϯ19 pmol/mg protein, oWKY 125Ϯ22 pmol/mg protein; PϽ0.05) and was not significantly different when compared with young WKY and young SHR ( Figure 2B ). The increase in the formation of cGMP by YC-1 was abolished in all groups in the presence of ODQ (10 mol/L) (data not shown).
␣ 1 /␤ 1 Subunit Expression of sGC in Thoracic Aorta, Heart, Kidney, and Brain
In aortic rings, protein expression of ␣ 1 and ␤ 1 subunits of sGC was significantly reduced in young and aging SHR when compared with age-matched WKY ( Figure 3A and 3B) . In contrast, expression of sGC protein (␤ 1 and ␣ 1 subunits) was not significantly different in hearts and kidneys from young WKY versus young SHR. Instead, sGC expression was found to be increased in aging WKY and SHR when compared with young WKY and SHR. However, there was no difference in the expression of sGC in hearts and kidneys from aging WKY and SHR ( Figures 4A and 4B and 5A and 5B). These sGC protein expression patterns were reflected in the steady-state levels of ␣ 1 /␤ 1 sGC mRNA, as revealed in RT-PCR experiments from the same organs ( Figures 3C, 4C , and 5C). Interestingly, no difference in the expression of sGC (␣ 1 and ␤ 1 subunits) protein was detected in brains from young and aging WKY and SHR (data not shown).
cGKI␣ mRNA Expression in Thoracic Aortas and Hearts
In aortic rings, expression of cGKI␣ mRNA was significantly reduced in young and aging SHR when compared with age-matched WKY ( Figure 6 ). However, there was no difference between the expression of cGKI␣ mRNA in hearts of WKY and SHR, but expression was found to be increased in hearts from aging WKY and SHR when compared with young rats (Figure 7 ).
Discussion
Several cardiovascular disorders, such as atherosclerosis and hypertension, are associated with endothelial dysfunction, which is characterized by an impairment of vasodilatormediated release of NO from the endothelium. In contrast, the endothelium-independent relaxant response of the vascular smooth muscle to NO donor compounds is thought not to be affected. 18 In the present study, we investigated a potential pathophysiological alteration of the sGC/cGMP pathway downstream of NO synthesis in SHR, an animal model of genetic predisposition to develop arterial hypertension during aging.
In SHR, specifically in the aorta, we found a significant reduction in mRNA and protein expression of both sGC 
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subunits when compared with control WKY, which correlated with decreased basal intracellular cGMP levels. Moreover, mRNA expression of the cGMP target protein GK-I, which is essential for cGMP-dependent vascular smooth muscle relaxation, 28 was also decreased in SHR aorta. A similar reduction of sGC␤ 1 expression has been recently reported for aging and, thus, hypertensive SHR. 20 In the present study, we observed reduced sGC and GK-I expression levels in young, normotensive SHR (6 weeks). Importantly, expression did not decrease further with age-dependent onset of hypertension. These findings demonstrate that tissuespecific downregulation of cGMP pathway components is an early event in the pathogenesis of hypertension and thus may be of pathophysiological relevance. Interestingly, we observed an impairment of the endothelium-independent relaxant response exclusively in aging SHR, as evidenced by a significant increase of the EC 50 value for YC-1 to induce vasorelaxation. This finding was surprising, as endothelium-independent vasorelaxation is thought not to be affected in SHR and other model systems of hypertension. 18 Moreover, it cannot be readily correlated with the observed reduction of sGC and GK-I expression, because the relaxation response was normal in young, normotensive SHR, despite low basal cGMP levels. This decreased basal content of cGMP in aortic segments from young SHR was however not due to an increase in cGMP breakdown, because the relaxant response to the selective PDE V inhibitor zaprinast was not significantly reduced in aortic rings from young SHR when compared with WKY. Importantly, impaired YC-1-induced relaxation in aging SHR was partially restored by SOD. This suggested that an increased O 2 Ϫ production was involved in the observed relaxation defect. In fact, excessive vascular O 2 Ϫ production is thought to be involved in the pathomechanism of hypertension, 17 because normal endothelial function and blood pressure could be restored by SOD 16 or by inhibitors of the xanthine oxidase system. 16, 29 It has been suggested that the rapid formation of the cytotoxic metabolite of NO and O 2 Ϫ , peroxynitrite, reduces the bioavailability of NO. 17 Moreover, the fact that impaired YC-1-induced relaxation in aging SHR was partially restored by SOD may be explained also by a direct inhibition of stimulated sGC activity by vascular O 2 Ϫ . 30 A similar impairment of endothelium-independent vasorelaxation, induced by SNP, has recently been described for 63-week-old SHR, which, however, was not reversed by SOD. 20 Therefore, these data collectively suggest that the sGC/cGMP pathway downstream of NO is specifically affected in hypertensive SHR; the functional impairment, however, is rather a late event in pathogenesis and, hence, might have escaped previous studies.
Endothelium-independent relaxation was not impaired in young, normotensive SHR, although sGC expression and intracellular basal cGMP levels were reduced. Interestingly, upon stimulation with YC-1, similar intracellular cGMP levels were reached in both young SHR and age-matched control rats, implying an apparently 10-fold increased sensitivity of the cGMP response to YC-1 in the former animals. It must be elucidated whether this sensitization is either directly mediated by changes in the sensitivity of sGC or mediated by a decrease in cGMP breakdown. Interestingly, we observed sensitization toward YC-1 in old WKY versus young WKY, as has been reported for the nitrovasodilator drug SNP in aging normotensive rats. 31 This suggests a developmental sensitization effect in healthy animals, which may, together with an age-dependent increase in vascular NOS expression, 32 provide an important adaptation mechanism that at least transiently can compensate for a diminished endothelium-dependent response to endothelium-dependent vasodilator upon aging. 31, 32 Downregulation of sGC subunits has been observed in several cell types and occurs in response to several physiological signaling molecules such as nerve growth factor 33 and cAMP. 26 In agreement with the present study, downregulation of sGC protein frequently coincides with decreased sGC mRNA levels 26, 34 and seems to involve sGC mRNA destabilization. 33 In vascular smooth muscle cells, sGC expression was inhibited by NO in a cGMP-dependent manner, suggesting a negative autoregulatory mechanism. 34 Interestingly, cGK-I expression was also found to be reduced in response to NO and cGMP in vascular smooth muscle cells. 35 Strikingly, expressional regulation of sGC␣ 1 , sGC␤ 1 , and cGK-I in SHR aorta, as well as in heart of aging rats was concertedly affected. This suggests the intriguing possibility that all 3 components of the cGMP pathway may underlie a common transcriptional control. It must be elucidated whether elevated amounts of aortic NO, produced by vascular NOS II upon inflammatory processes and endothelial damage in SHR, 36 affect sGC and GK-I expression. On the other hand, a tissue-specific defect in transcriptional control may contribute to the genetic predisposition of SHR for arterial hypertension.
Developmental regulation of sGC expression was described for rat lung, in which the sGC content decreased after lung maturation in the newborn. 37 In the present study, we show an age-dependent increase in sGC and GK-I expression in rat heart, which was independent of the hypertensive phenotype. The physiological relevance of this phenomenon remains to be clarified. The increased expression of sGC and cGK-I upon aging in heart, but not in brain, suggests a prominent role in cardiovascular control, possibly as part of the adaptation mechanism discussed above. In contrast to SHR, reduced expression of sGC␤ 1 mRNA in the kidney has been associated with elevated blood pressure in an animal model of salt-sensitive hypertension. 38 Instead, mRNA levels of sGC␤ 2 , a kidney-specific sGC subunit, 39 were increased, presumably leading to the formation of NO-insensitive ␣ 1 /␤ 2 heterodimers. 38 The pathophysiological relevance of this observation remains to be elucidated.
Taken together, full development of hypertension in SHR is a multifactorial process. In the early phase, a reduction in sGC, cGMP, and the cGMP receptor, cGK-I, was observed, which, at this stage, can be functionally compensated to the effect that blood pressure stays normotensive. At later stages, increased O 2 Ϫ formation reduces the availability of NO and further affects the sGC pathway to a level that cannot be functionally compensated, leading to development of arterial hypertension. Whether early impairment of the sGC pathway triggers the onset of other factors relevant for pathogenesis, such as O 2 Ϫ formation, reduction of endothelial NO synthesis, or development of inflammatory processes, remains to be elucidated.
